Reuters -- Merck & Co’s experimental blood clot preventer vorapaxar can cause bleeding in patients who previously suffered a stroke, the drugmaker confirmed on Wednesday. Merck said last week that an independent committee to monitor clinical trials of the drug determined that vorapaxar was inappropriate for patients with a history of strokes.
